Polygenic risk score as a determinant of risk of non-melanoma skin cancer in a European-descent renal transplant cohort
Year: 2018
Type: article
Study design: Observational Study
Abstract: Renal transplant recipients have an increased risk of non-melanoma skin cancer (NMSC) compared to in the general population. Here, we show polygenic risk scores (PRS) calculated from genome-wide association studies (GWAS) of NMSC in a general, nontransplant setting, can predict risk of, and time to posttransplant skin cancer. Genetic variants, reaching predefined P -value thresholds were chosen from published squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) nontransplant GWAS. Using these GWAS, BCC and SCC PRS were calculated for each sample across three European ancestry renal transplant cohorts (n = 889) and tested as predictors of case:control status and time to NMSC posttransplant. BCC PRS calculated at P -value threshold 1 × 10 −5 was the most significant predictor of case:control status of NMSC posttransplant (OR = 1.61; adjusted P = .0022; AUC [full model adjusted for clinical predictors and PRS] = 0.81). SCC PRS at P -value threshold 1 × 10 −5 was the most significant predictor of time to posttransplant NMSC (adjusted P = 9.39 × 10 −7 ; HR=1.41, concordance [full model] = 0.74). PRS of nontransplant NMSC is predictive of case:control status and time to NMSC posttransplant. These results are relevant to how genomics can risk stratify patients to help develop personalized treatment regimens.
DOI: 10.1111/ajt.15057
Institutions: Royal College of Surgeons in Ireland, Vanderbilt University, Vanderbilt University Medical Center, Queen's University Belfast, University of Glasgow, University of Iowa, University of Iowa Hospitals and Clinics, Utrecht University, University Medical Center Utrecht, NHS Lothian, Edinburgh Royal Infirmary, Beaumont Hospital, University of Pennsylvania
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,300
Awards: Discovery of an integrated risk profile for chronic kidney disease and development of a clinical biomarker panel for personalising medicine, G2311296441, Pharmacogenomics of Tacrolimus and New Onset Diabetes After Kidney Transplant, G3177098586, G4432921003, G6071898252, The Vanderbilt Institute for Clinical and Translational Research (VICTR), G8173526563
OpenAlex ID: W2885588086
